莫洛替尼与帕西替尼治疗骨髓纤维化患者安全性及贫血转归的间接治疗比较
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.
作者信息
Masarova Lucia, Verstovsek Srdan, Palandri Francesca, Mesa Ruben, Harrison Claire, Dobi Balázs, Gorsh Boris, Wang Zhaohui, Ellis Catherine, Patnaik Dwaipayan, Liu Tom, Kapetanakis Venediktos
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
出版信息
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
AIM
To perform an indirect treatment comparison of safety and anemia outcomes between the Janus kinase (JAK) inhibitors momelotinib and pacritinib in patients with myelofibrosis.
METHODS
Treatment-emergent adverse events (AEs) and anemia outcomes were compared in a pooled population of JAK inhibitor - experienced and - naive patients treated with momelotinib (SIMPLIFY-1/SIMPLIFY-2/MOMENTUM) or pacritinib (PERSIST-2/PAC203).
RESULTS
Momelotinib had statistically significantly lower odds and risk for all grades of diarrhea, nausea, peripheral edema, and vomiting as well as grade 3/4 and serious AEs vs pacritinib. Momelotinib-treated patients also had greater odds/possibility of hemoglobin improvement of ≥ 1 g/dL and clinical improvement in hemoglobin.
CONCLUSIONS
Momelotinib provides a more favorable safety profile and a higher chance for hemoglobin improvement vs pacritinib.
目的
对骨髓纤维化患者中，Janus激酶（JAK）抑制剂莫美替尼和帕可替尼的安全性及贫血相关结局进行间接治疗比较。
方法
在接受过JAK抑制剂治疗和未接受过JAK抑制剂治疗的患者合并人群中，比较接受莫美替尼（SIMPLIFY-1/SIMPLIFY-2/MOMENTUM）或帕可替尼（PERSIST-2/PAC203）治疗后出现的治疗中不良事件（AE）及贫血相关结局。
结果
与帕可替尼相比，莫美替尼在所有级别的腹泻、恶心、外周水肿和呕吐以及3/4级和严重AE方面的发生率和风险在统计学上显著更低。接受莫美替尼治疗的患者血红蛋白改善≥1 g/dL及血红蛋白临床改善的几率/可能性也更高。
结论
与帕可替尼相比，莫美替尼具有更良好的安全性，且血红蛋白改善的机会更高。
Zotero 插件